The global pharmaceuticals market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%, according to a recent pharma market research report by The Business Research Company.

The global market for clinical trial services to biopharmaceutical, biotechnology, and medical device companies is forecast to grow at 12% year on year up to 2021, according to a new report. That is an acceleration from its rate of 10% up to 2017 which raised its value to $44.4 billion. The businesses that provide outsourcing in clinical trials are CROs.

As U.S. obesity rates climb and Americans age, more people are developing sleep apnea, restless leg syndrome, and other sleep disorders. Plus, stressors related to the volatile stock market, terrorism, mass shootings, health care, student debt, and protests against politicians are all resulting in more sleepless nights.

The US Federal Drug Administration is aiming to cut the time-to-market and the development costs for new drugs. This will help drive the market for biologics — where over 1,000 drugs are currently under development — to 9.6% year-on-year growth from its recent rate of 5.4%.

According to a new report from Irish research company GMR Data, the global healthcare packaging market will grow to $262bn by 2028, rising from $117.2bn across 2018.

The increasing demand for biologics, patent expiry of blockbuster molecules, and a limited number of potential products in the pipeline have driven companies to adopt new technologies such as single-use bioprocessing technologies which are cost-effective and enable the quick turnaround of products.

Although we still do not know the specific causes of autism, we do know one thing. The rate is increasing, and the market for treatment is growing.

Based on new government data, 1 in 45 children in the United States, aged 3-17, have autism. This is up from only 1 in 150 children back in 2000.

Orphan disease, by definition, is “any disease that affects a small percentage of the general population.” These diseases are often life-threatening, chronic, progressive, degenerative, and disabling, while most of them are linked to a genetic disorder and remain undiagnosed.

The U.S. weight loss market is estimated to be worth $68.2 billion in 2017—a 2.7% gain, and growth should continue into 2018, when the market is expected to post a better gain of 3.2% to $70 billion.

Continued high rates of obesity and overweight, coupled with low unemployment and higher disposable income, are boosting the market. However, performance will vary significantly by individual market segment.

The past few decades have witnessed several blockbuster drug performances in the pharma industry, changing the face of the industry as well as completely transforming the fate of many companies and stakeholders. The success of these drugs justifies the rigorous process of development, which is tough and economically draining.